Biotech in 2025: Investment Trends, Congress, and Approvals

In this year-in-review episode, we break down key biotech investment trends from 2025, major policy developments in Congress, and what they mean for innovation and patients. The conversation covers defense-related biotech priorities, healthcare affordability challenges, PBM reform efforts, and capital access for early-stage companies. We also preview new data on venture investment, emerging therapeutic areas, and AI-enabled drug development. The episode closes with a look at recent FDA approvals that highlight real progress reaching patients. What stood out to you most in the 2025 biotech investment data?How do you see policy shaping innovation and capital formation in the year ahead?Which FDA approval gives you the most optimism for patients?If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPodhttps://www.instagram.com/makingmedicinepod/https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=trueTimestamps:0:00 Disclaimers and welcome0:23 Year in review overview: biotech, policy, and innovation0:45 Congress wraps up the year and the FY2026 NDAA1:32 Healthcare legislation and premium pressures3:19 PBM reform efforts and legislative outlook5:39 Capital access update and the Invest Act7:32 2025 biotech investment data preview8:00 Leading therapeutic areas and rare disease trends8:41 Geographic investment highlights by state9:21 Investment by congressional district10:16 AI-enabled biotech investment trends10:46 FDA approvals corner12:31 Closing thoughts and year-end reflectionsDISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.